Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Novartis logo

Novartis

Status and phase

Active, not recruiting
Phase 1

Conditions

Progressive Supranuclear Palsy (PSP)

Treatments

Drug: placebo
Drug: antisense oligonucleotide

Study type

Interventional

Funder types

Industry

Identifiers

NCT04539041
CNIO752A02101

Details and patient eligibility

About

This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.

Full description

This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants. Approximately 58 PSP participants in 5 cohorts will be randomized to receive NIO752 or placebo in a ratio of 3:1. Intrathecal (IT) injections will be given multiple times over 3 months and participants will remain in study for an additional 9-month follow-up period; or will be given multiple times over 9 months and participants will remain in study for an additional 3-month follow-up period. Cohorts will be enrolled sequentially. Safety assessments will include physical and neurological examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), CSF laboratory test, adverse event, and serious adverse event monitoring.

Enrollment

59 patients

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent
  • Between 40 to 75 years old (inclusive)
  • Have PSP diagnosed for less than 5 years with a current classification of probable PSP Richardson syndrome, a progressive supranuclear palsy rating scale (PSPRS) score < 40 and MOCA score >17 at screening
  • Be able to ambulate independently or able to take at least 5 steps with minimal assistance
  • At least a 12-month history of postural instability or falls within 3 years from disease onset as per medical history
  • Vertical supranuclear gaze palsy, or reduced velocity of vertical saccade

Able and willing to meet all study requirements including:

Have a study partner who is reliable, competent, and at least 18 years of age, and will be able to accompany the participant to study visits, be knowledgeable of the participant's ongoing condition during the study to provide study related information to study site when required both in person and via a phone Reside in a proximity to the study site to allow a timely unscheduled visit if necessary (ideally less than 2 hours) Able to undergo lumbar puncture (LP), CSF draws and blood draws

If the participant is receiving levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, catechol-o-methyltransferase (COMT) inhibitor, rasagiline, CoQ10 or other Parkinson's medications, acetylcholinesterase inhibitors, antipsychotics, memantine, or other non-tau modifying Alzheimer's medication the dose must have been stable for at least 30 days prior to the screening visit and must remain stable for the duration of the study. No such medication can be initiated during the study.

Exclusion criteria

  • Live in a skilled nursing facility or dementia care facility
  • Evidence of motor neuron disease, or any other neurological disease that could explain symptoms
  • Clinically significant laboratory abnormality
  • Attempted suicide, suicidal ideation with a plan that required hospital admission within 12 months prior to Screening. In addition, patients deemed by the Investigator to be at significant risk of suicide, major depressive episode, psychosis, confusion state, or violent behavior should be excluded.
  • A clear and robust benefit from levodopa by history
  • Use of lithium, methylene blue or other putative disease modifying drugs for PSP within 30 days of screening
  • Any previous use of experimental therapy within 30 days or 5 half-lives prior to Day 1, whichever is greater
  • Any condition that increases risk of meningitis unless participant is receiving appropriate prophylactic treatment
  • History of post-lumbar-puncture headache of moderate or severe intensity and/or blood patch

11. Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned during the study 12. Unable to undergo magnetic resonance imaging (MRI) due to for example claustrophobia, or presents absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator) 13. Patients with other significant brain MRI abnormalities by history or at screening.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

59 participants in 6 patient groups, including a placebo group

Cohort A NIO752
Experimental group
Description:
4 injections of NIO752 at dose A
Treatment:
Drug: antisense oligonucleotide
Cohort B NIO752
Experimental group
Description:
4 injections of NIO752 at dose B
Treatment:
Drug: antisense oligonucleotide
Placebo
Placebo Comparator group
Description:
4 injections of placebo
Treatment:
Drug: placebo
Cohort C NIO752
Experimental group
Description:
4 injections of NIO752 at dose C
Treatment:
Drug: antisense oligonucleotide
Cohort D NIO752
Experimental group
Description:
4 injections of NIO752 at dose D
Treatment:
Drug: antisense oligonucleotide
Cohort E NIO752
Experimental group
Description:
4 injections of NIO752 at dose E
Treatment:
Drug: antisense oligonucleotide

Trial contacts and locations

12

Loading...

Central trial contact

Novartis Pharmaceuticals; Novartis Pharmaceuticals

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems